IMPROVING HEALTH OUTCOMES THROUGH TRUSTED DATA EXCHANGE

trustplatform.sg

"Trusted Research and Real world-data Utilisation and Sharing Tech"

Koh Mingshi Director, TRUST Office, MOHT

SCRI Clinical Trial Symposium, 31 Jul 2024

Jointly developed by:









Agenda

- What is TRUST?
- How we enable safe and efficient data linkage and analytics
- What is on the horizon
- Supporting clinical trials design and research



IMPROVING HEALTH OUTCOMES THROUGH TRUSTED DATA EXCHANGE

What is TRUST 'Trusted Research and Real world-data Utilisation and Sharing Tech'

How TRUST addresses key data challenges faced by researchers

UNCLEAR DATA ACCESS RULES



CLARIFY PERMISSIBILTY OF USE; OPEN UP ACCESS

- Data permissibility rules and governance for key datasets has been clarified.
- Streamlined **pre-agreements** with data custodians and users.
- Established central Data Access Committee for streamlined and efficient data approval.

VARIED DATA SECURITY & INFRASTRUCTURE



NATIONAL DATA-EXCHANGE PLATFORM

- Established secure environment on Government Commercial Cloud for data linkage, access and analysis
- Established **Trusted Third Party to enable linkages across datasets** and anonymisation tool according to MOH anonymisation standards.

LACK DATA STANDARDS



- Adopted internationally recognised data standard (e.g. OMOP*).
- A central data curation team has been set up and OMOP mapping work is ongoing.

^{*}Observational Medical Outcomes Partnership (OMOP)

TRUST is a data framework and platform to enable health analytics across datasets One stop to request, access and analyse data TRUST Secure cloud analytical environment within Government Commercial Cloud Anonymised | Anonymised Strategic Research Data Real-World Data and transfer I ı and transfer in their own repositories or data **Real-World Data** in Vault or Govt agencies' Strategic Research Data aggregators e.g. A*STAR repository BiomedDAR MITTROCT CADENCE SGUSTO Anonymised linked datasets for analysis

"Trusted Research and Real world-data Utilisation and Sharing Tech" Platform

TRUST have enabled high value health-data analytics research

Project #1: Linkage of Genomic-phenotypic-clinical data for Precision Medicine studies

Support development of analytical pipelines to enable next phase of Precision Medicine studies in diseases such as cardiovascular, metabolic, neurological, psychiatric, ophthalmologic, as well as rare diseases. Project #2: Linkage of Clinical-lifestyle-social data for better understanding of the social determinants of health to improve cardiovascular health outcomes

Generate new insights into determinants that influence cardiovascular health and equity, to better design interventions for impactful and sustainable cardiovascular outcomes.

Project #3: Linkage of clinical-lifestyle data for transforming Chronic Care for Diabetes, Hypertension & Hyperlipidemia (DHL)

JARVIS

Reduce complication rate in DHL patients by 20% over 5 years through AI models that are built on local real-world data, develop preventive measures and treatment optimization.

Project #4: Linkage of Genomic-clinical data for COVID-19 genomic risk factor study





Assess the prevalence and allele frequencies of host genetic variants determining the susceptibility and severity of SARS-CoV-2 infections in Singapore residents.



Currently, TRUST offers ~40 datasets across the following domains

List updated as of July 2024

Population







Social









Economic



Housing



*subject to MOE approval

Health









Case & Visit



Laboratory

Diabetes

₩ ₩





Comorbidity

<u>-</u>)向-

Accident &

Emergency



Beds

Radiology

Health Finance







Lifestyle / Preventive Care



iQuit Smoking



Sleep Tracking Activity







图

Disease Registry












TRUST growing usership



- For access to data catalogue, training materials and TRUST data request application forms
- TRUST Membership grew with an average of ~65 new members each quarter in 2023
- Q2 2024 data up to 7 June 2024
- Does not include TRUST staff and deactivated accounts




- For access to data analytics portal based on approved TRUST Data Request by TRUST DAC
- TRUST Usership grew with an average of ~24 new users each quarter in 2023 and had the highest jump of 44 users from Q1 to Q2 2024
- Q2 2024 data up to 7 June 2024



- TRUST use cases grew with an average of ~3 new use cases each quarter in 2023
- Q2 2024 data up to 7 June 2024


TRUST Use Cases



- Available TRUST datasets grew most significantly in 2022 by 20 datasets when TRUST was gearing up for operation.
- Data up to 7 June 2024

3. TRUST Usership


Breakdown of usership by institution




- Majority of TRUST Users come from NUS (39%)
- Data is accurate up to 7 June 2024

Notes

- · Does not include TRUST staff
- Deactivated accounts are due to staff resignations from Organisation



Majority of TRUST Use Cases support analytics
 OFFICIAL (CLOSED) — NON-Gally Scotton of the control of



 Majority of TRUST Use Cases come from large national research programmes

Key highlights in current phase of development to facilitate data access and sharing

Promulgated data sharing principles and best practices



Established pre-agreements with 12 Public Research Organisations to enable expeditious data access (af 22 April 2024)

























Support more genomics & low/no code analysis by 2H 2024



Initiated National level effort to harmonise data standard

- ~60% clinical data
 mapped to OMOP CDM*
- Established national partnerships and curation team on OMOP mapping

How do we enable safe and efficient data linkage and analytics

TRUST's core features are built on the 5 Safes Framework, ensuring safe data access



SAFE PURPOSE

All data requests will be reviewed by TRUST Data Access Committee to ensure that purpose of use fulfils public interest and social value.



SAFE PEOPLE

TRUST users must have appropriate credentials for access to TRUST and the approved data for research.



SAFE SETTINGS

TRUST is hosted in a secure environment with government-standard security measures.



SAFE DATA

All data accessed on TRUST are anonymised to government standards to reduce re-identification risks.




SAFE OUTPUT

Only verified aggregate data and insights with low re-identification risk can be output.

Deploy synergistic policy and technical solutions across the data lifecycle
Balance privacy & public interest with safe use of data
Improved health outcomes & better care delivery

TRUST adopts the Five Safes Framework



TRUST DAC



Mr Philip Ong (Chair)
DS (Development), MOH



Mr Lai Kai Bin DD, GDO, SNDGO



Ms Lim Yi Ding D, DOS/TC



A/Prof Yeo Khung Keong Dy GCMIO (Research), SHS



A/Prof Ngiam Kee Yuan GCTO, NUHS



A/Prof Tan Cher Heng GCRO, NHG



Prof Chng Wee Joo Vice President (Biomedical Science Research), NUS



Prof. Roger Vaughan D, CQM & CSSD, Duke-NUS



Dr Sebastian Maurer-Stroh Executive Director, BII, A*STAR



Prof John Chambers Prof, CVD Epi, NTU CSO, PRECISE



Prof Julian Savulescu
D, Centre for Biomedical Ethics
(Ethics Domain)



Prof Simon Chesterman Vice Provost (Educational Innovation), NUS (Legal Domain)




Ms Ai Ling Sim-Devadas DD (Advocacy & Engagement), LKCSOM, NTU



Mr Rajakanth Raman ED, Rainbow Across Borders

Ensuring Data User's expeditious and safe access




- a. Approval of data output by TRUST Data Concierge.
 - All output must comply with TRUST's output policy, which states that these must be aggregated/de-identified, generated based on data from at least 5 individuals.
- b. Verification that public release of analysis is within scope of approved request.
 - Researchers who wish to publish insights generated from their research on TRUST are required to submit their publications to TRUST DAC secretariat for pre-publication review.

TRUST portal as launch point for user to access various features and functions

Key Features and Function


- Access to Jupyter Lab via Sagemaker Studio
 - Support on Python, R, Pyspark, and SparkR
- Genomic Tools (2H 2024)
 - Hail in Sagemaker Studio
 - Lifebit genomic platform
 - Cohort Browser for minimal code experience
 - Genomic analysis pipelines
- Export analytical insights and findings with just a few clicks
- Send your enquiries from within the portal



User Onboarding, Training and Support

- Since launched, TRUST has made available ~40 datasets, approved ~20 data requests and supported approximately ~150 users on their research analytics.
- We are actively engaging researchers to understand their research questions and to support their data needs.
- Users are supported with an onboarding programme by the TRUST team, augmented with additional resources available through the TRUST portal
 - User guides and Onboarding sessions
 - Step-by-step video tutorials
 - Community / peer forum*

A TRUST Data Concierge team supports users throughout their journey



"We are extremely grateful towards the TRUST Support team for their generous support and great responsiveness and guidance, thank you!" - Dr Chen Wenjia, SSHSPH, NUS (first batch of TRUST users)

^{*}to be launched in 2H 2024



New opportunities

Increasing Impact



- Enable unstructured data (e.g., free text clinical notes, retinal images) and broaden data types (e.g. geospatial)
- Support strategic industry partners

- Future-proof with Privacy Preserving Tech (e.g. federated analysis)
- Enhance interoperability with other Trusted Research Environments local and internationally

Increasing Interoperability



Enhancing experience



- Scaling and automation (e.g. output checking)
- Enable self-serve (e.g. data exploration & visualisation)
- Develop "TRUST academy" training programmes (e.g. data governance, best practices for data sharing and management)

Further interoperability with the wider ecosystem to further health data innovations





Trusted Research Environments

Local data platforms, e.g.





BioMed DAR

Overseas data platforms, e.g.







(in discussion)

Supporting clinical trials design and research

Supporting clinical trials design and research with real world data

Support hypothesis generation –

- <u>Identify trends</u> to inform the design of new trials e.g. uncover patterns of treatment responses or adverse effects based on multi-modal datasets
- Refine the inclusion/exclusion criteria, ensuring the trial is more focused and relevant.
- Historical data can provide a <u>baseline comparison</u> for new trial results, helping to establish benchmarks and norms.

Support more efficient and effective clinical trials -

- Analysis of past anonymized data can highlight potential risks and adverse effects, allowing for <u>better mitigation strategies</u> in the trial design.
- Support simulations and power analyses to <u>determine the optimal clinical trial</u> <u>sample size</u> needed to detect a meaningful effect, optimizing resource allocation.
- <u>Track participants longitudinally</u> without compromising their privacy to observe health outcomes and treatment effects.

Using real world data with care

- Trial and real-world populations are different, should be cognizant of the efficacy-effectiveness gap;
- Confounding factors influencing the outcome need to minimized e.g. careful study design or through data analysis.
- Selection biases may be introduced e.g. when the observed subgroup of patients is not representative of the broader population of interest and need to be adequately dealt with.

